But the fact is that this program--I know some efforts have been made to increase to 90 percent the guarantees and do other things under the 7(a) program. But it basically is not seen as a great friend in a moment like this.

there's always a resistance I think, to some degree, on overburdening these efforts with minute conditionality, because it would be counterproductive.

We are not quite there yet.

This is a subject matter that is going to consume a lot of this Committee's time and attention.

I hope that TARP can be wound down in the right way at the appropriate time in manner more deliberative and well thought out than the process by which it was created and implemented.

If this is going to take time for the normal private commercial lending operations to open up their doors, something better needs to be done by the SBA, because it is just not seen as an ally and a friend on their side in this matter.

the major thrust here was to try and get resources--75 members of this body, many of whom knew the political consequences.

I do not want to dwell on the SBA, but I got to tell you, you mention the word 'SBA'--and all of us have done this to audiences back home--and you get a roll of the eyes.

I have just got to say, Mr. Secretary--and then I am going to move right on to Senator Corker--when you see what access we have to Chinese markets with U.S. products, it is terribly frustrating, to put it mildly.

It seems to me we ought to be pursuing this more aggressively than paying 100 percent on the dollar to this.

This is an industry that has been devastated in terms of employment.

I have been under the impression we were going to try and craft something legislatively to deal with the resolution mechanism generally.

I thank you for your willingness to do that.

Strong enforcement promotes investor confidence and participation in these markets.

I cannot remember a time when the need for strong, independent leadership at the FDA was more critical.

I, along with others, authored that Better Pharmaceuticals Act for Children, which has been remarkable.

The last 8 years of repression, of dissent, and political ideology trumping science-based decisionmaking have left an agency weakened as a result.

The SEC's Division of Enforcement has a vital role in promoting compliance with the securities laws.

I am pleased that the Securities Subcommittee is holding today's hearing and commend my colleague, Senator Reed, for his work to enhance the performance of the Securities and Exchange Commission.

It is critical to promoting the integrity, fairness, and efficiency of U.S. financial markets.

Studies done under the Better Pharmaceutical Act for Children have proven, just how important this area is.

I chair the Subcommittee on Children and Families and have for a long time.

I have authored the legislation on pediatric medical devices as well for much of the same reason.

Make no mistake about it--this position is as important as any that this committee we will consider.

I think probably this job--I know the Secretary of Health and Human Services is obviously a critical job as is the Secretary of Education.